Unknown

Dataset Information

0

Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment.


ABSTRACT: We isolated a SARS-CoV-2 BA.2 variant from a person with COVID-19 recrudescence after nirmatrelvir/ritonavir treatment. Antiviral sensitivity and neutralizing antibody testing were performed with both parental SARS-CoV-2 and multiple variants of concern. We found that neither NM resistance nor absence of neutralizing immunity were likely causes of the recrudescence.

SUBMITTER: Carlin AF 

PROVIDER: S-EPMC9278181 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment.

Carlin Aaron F AF   Clark Alex E AE   Chaillon Antoine A   Garretson Aaron F AF   Bray William W   Porrachia Magali M   Santos AsherLev T AT   Rana Tariq M TM   Smith Davey M DM  

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20230201 3


We isolated a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.2 variant from a person with coronavirus disease 2019 recrudescence after nirmatrelvir/ritonavir treatment. Antiviral sensitivity and neutralizing antibody testing were performed with both parental SARS-CoV-2 and multiple variants of concern. We found that neither nirmatrelvir resistance nor absence of neutralizing immunity was a likely cause of the recrudescence. ...[more]

Similar Datasets

| S-EPMC9128786 | biostudies-literature
| S-EPMC9619622 | biostudies-literature
| S-EPMC9384370 | biostudies-literature
| S-EPMC11403474 | biostudies-literature
| S-EPMC9216730 | biostudies-literature
| S-EPMC10478155 | biostudies-literature
| S-EPMC10644265 | biostudies-literature
| S-EPMC7270518 | biostudies-literature